Resources VIDEOS 00:48 Are your T2D patients on the right DPP4i dose? 00:38 DPP4i - Proven efficacy with no dose reduction 00:27 DPP4i – What efficacy to expect? 00:54 Efficacy, Safety, Simplicity all in one DPP4i 01:22 JENTADUETO® dosing information 00:38 Renally impaired patients - Are they on the right dose? 00:21 Restricting TRAJENTA® to only renally impaired patients 03:20 High Residual CV Risk 03:20 EMPA-REG OUTCOME Results - Video 03:20 Value Proposition 02:23 Are patients with type 2 diabetes at elevated CV risk? 02:23 Is Jardiance a medication for both endocrinologists and cardiologists? 01:52 Is the glucose-lowering effect of Jardiance a barrier to cardiologists prescribing it? 06:36 Do you use Empagliflozin for CV risk reduction in T2DM patients? 02:46 Should we move beyond glucose lowering as the main treatment goal? 01:42 What are your thoughts on the 35% relative risk reduction? 02:22 What are your views on the 38% relative risk reduction in CV death with Jardiance? 01:56 What does lowering the risk of CV death? - John Wilding 01:51 What does lowering the risk of CV death? - Lars Ryden 02:29 What were the key findings from EMPA-REG OUTCOME? 03:15 Actilyse Dosing 01:18 Treatment 02:22 Causes for stroke and its Diagnosis Load more
